DK0697111T3 - Celle-afprøvning for Alzheimers sygdom - Google Patents

Celle-afprøvning for Alzheimers sygdom

Info

Publication number
DK0697111T3
DK0697111T3 DK94915953.7T DK94915953T DK0697111T3 DK 0697111 T3 DK0697111 T3 DK 0697111T3 DK 94915953 T DK94915953 T DK 94915953T DK 0697111 T3 DK0697111 T3 DK 0697111T3
Authority
DK
Denmark
Prior art keywords
alzheimer
disease
cell testing
cells
intracellular calcium
Prior art date
Application number
DK94915953.7T
Other languages
English (en)
Inventor
Daniel L Alkon
Rene Etcheberrigaray
Ito Etsuro
Gary E Gibson
Original Assignee
Cornell Res Foundation Inc
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell Res Foundation Inc, Us Health filed Critical Cornell Res Foundation Inc
Application granted granted Critical
Publication of DK0697111T3 publication Critical patent/DK0697111T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Physiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK94915953.7T 1993-05-03 1994-05-02 Celle-afprøvning for Alzheimers sygdom DK0697111T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/056,456 US5580748A (en) 1993-05-03 1993-05-03 Diagnostic tests for alzheimers disease

Publications (1)

Publication Number Publication Date
DK0697111T3 true DK0697111T3 (da) 1998-03-02

Family

ID=22004526

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94915953.7T DK0697111T3 (da) 1993-05-03 1994-05-02 Celle-afprøvning for Alzheimers sygdom

Country Status (12)

Country Link
US (1) US5580748A (da)
EP (1) EP0697111B1 (da)
JP (1) JPH09500202A (da)
AT (1) ATE155888T1 (da)
AU (1) AU689776B2 (da)
CA (1) CA2162048A1 (da)
DE (1) DE69404460T2 (da)
DK (1) DK0697111T3 (da)
ES (1) ES2108455T3 (da)
GR (1) GR3025126T3 (da)
HK (1) HK1001500A1 (da)
WO (1) WO1994025872A1 (da)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5976816A (en) * 1993-05-03 1999-11-02 The United States Of America As Represented By The Department Of Health And Human Services Cell tests for alzheimer's disease
US6300085B1 (en) 1993-05-03 2001-10-09 The United States Of America As Represented By The Department Of Health And Human Services Diagnostic method for Alzheimer's disease
US6107050A (en) * 1993-05-03 2000-08-22 The United States Of America As Represented By The Department Of Health And Human Services Diagnostic test for alzheimers disease
US6573063B2 (en) * 1995-10-04 2003-06-03 Cytoscan Sciences, Llc Methods and systems for assessing biological materials using optical and spectroscopic detection techniques
US5902732A (en) * 1995-10-04 1999-05-11 Cytoscan Sciences Llc Drug screening process measuring changes in cell volume
US6183975B1 (en) * 1997-02-24 2001-02-06 J. Jay Gargus Method of detection of congenital disease
JP2001523002A (ja) * 1997-11-10 2001-11-20 ブリストル−マイヤーズ スクイブ カンパニー アルツハイマー病の診断方法
US6087118A (en) * 1999-03-04 2000-07-11 Bristol-Myers Squibb Company Method for diagnosing alzheimer's disease
JP2003503083A (ja) * 1999-07-01 2003-01-28 サイオス，インコーポレーテッド アミロイド関連疾患の予防及び治療
WO2001077686A2 (en) * 2000-04-05 2001-10-18 Neurologic, Inc. Cellular calcium responce for diagnosis of alzheimer's disease
US6495335B2 (en) * 2000-12-07 2002-12-17 Mario Chojkier Compositions and methods for diagnosing alzheimer's disease
GB0107231D0 (en) 2001-03-22 2001-05-16 Imp College Innovations Ltd Patch clamp
US20080004332A1 (en) * 2002-03-07 2008-01-03 Alkon Daniel L Methods for alzheimer's disease treatment and cognitive enhancement
US20050065205A1 (en) * 2002-03-07 2005-03-24 Daniel Alkon Methods for Alzheimer's disease treatment and cognitive enhance
US6825229B2 (en) 2002-03-07 2004-11-30 Blanchette Rockefeller Neurosciences Institute Methods for Alzheimer's Disease treatment and cognitive enhancement
TW201207390A (en) 2004-05-18 2012-02-16 Brni Neurosciences Inst Method for screening agent for antidepressant activity
CA2617003A1 (en) * 2005-07-29 2007-02-08 Blanchette Rockefeller Neurosciences Institute Use of a pkc activator, alone or combined with a pkc inhibitor to enhance long term memory
RU2008115455A (ru) * 2005-11-03 2009-12-10 Рэдпойнт Био Корпорэйшн (Us) Высокопроизводительный скрининг-анализ ионного канала trpm5
CN103961347A (zh) 2006-07-28 2014-08-06 布朗歇特洛克菲勒神经科学研究所 刺激细胞生长、突触重塑和巩固长期记忆的方法
EP2121000B1 (en) * 2007-02-09 2015-09-23 Blanchette Rockefeller Neurosciences, Institute Therapeutic effects of bryostatins, bryologs, and other related substances on head trauma-induced memory impairment and brain injury
CL2007002908A1 (es) * 2007-10-09 2008-05-30 Univ Concepcion Procedimiento electroquimico in vitro para evaluar capacidad neurotoxica de estructuras, principios activos y/o compuestos de interes en celulas vivas y que comprende medir y cuantificar los parametros electricos en membranas expuestas a dichos agreg
CA2776501C (en) * 2009-10-02 2022-04-19 Blanchette Rockefeller Neurosciences Institute Fibroblast growth patterns for diagnosis of alzheimer's disease
WO2014183023A1 (en) 2013-05-09 2014-11-13 Trustees Of Boston University Using plexin-a4 as a biomarker and therapeutic target for alzheimer's disease
WO2015089375A1 (en) 2013-12-13 2015-06-18 The General Hospital Corporation Soluble high molecular weight (hmw) tau species and applications thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4925664A (en) * 1986-10-20 1990-05-15 University Of Utah Spider toxins and methods for their use as blockers of calcium channels and amino acid receptor function
EP0408650A1 (en) * 1988-04-08 1991-01-23 Massachusetts Institute Of Technology Method and composition for treating neurological disorders

Also Published As

Publication number Publication date
US5580748A (en) 1996-12-03
HK1001500A1 (en) 1998-06-19
ATE155888T1 (de) 1997-08-15
CA2162048A1 (en) 1994-11-10
GR3025126T3 (en) 1998-02-27
DE69404460D1 (de) 1997-09-04
AU6778494A (en) 1994-11-21
ES2108455T3 (es) 1997-12-16
WO1994025872A1 (en) 1994-11-10
DE69404460T2 (de) 1998-02-26
EP0697111A1 (en) 1996-02-21
EP0697111B1 (en) 1997-07-23
AU689776B2 (en) 1998-04-09
JPH09500202A (ja) 1997-01-07

Similar Documents

Publication Publication Date Title
DK0697111T3 (da) Celle-afprøvning for Alzheimers sygdom
ATE235057T1 (de) Cell test und diagnostischer kit für alzheimer- erkrankung
WO1999058981A3 (en) Diagnostic tests for alzheimer's disease
DE69312513D1 (de) MENSCHLICHE CYCLOOXYGENASE-2cDNA UND BESTIMMUNG VON MENSCHLICHE CYCLOOXYGENASE-2-INHIBIERUNG
WO2000066762A3 (en) Indicators of altered mitochondrial function in predictive methods for determining risk of type 2 diabetes mellitus
EP0671920A4 (en) AN ANTI-IDIOTYPICAL ANTIBODY AND ITS USE IN THE DIAGNOSIS AND THERAPY OF HIV-RELATED DISEASES.
ATE325343T1 (de) Diagnose und behandlung von arthritischen erkrankungen
ATE188036T1 (de) Glykoalkaloide
ATE250625T1 (de) IM WESENTLICHEN REINES ZONULIN ALS PHYSIOLOGISCHER MODULATOR VON ßTIGHT JUNCTIONSß BEI SÄUGERN
ES2151880T3 (es) Antagonistas de proteina de coagulacion de la sangre y sus utilizaciones.
ES2115679T3 (es) Preparacion de reactivos de tiempo de protrombina a partir de factor de tejido humano recombinante y de fosfolipidos sinteticos y naturales purificados.
DE69230890D1 (de) Bestimmung von nukleären matrixproteinen in flüssigkeiten
DE69530933D1 (de) Verwendung von 5-(tetradecyloxy)-2-furan carbonsäure für die behandlung von alzheimer krankheit oder psychosis
ES467222A1 (es) Procedimiento de preparacion de una emulsion del tipo agua en aceite o aceite en agua estable.
DE69333076D1 (de) Test und behandlung von demyelinierenden krankheiten wie multiple sklerosis
DE69616340D1 (de) Fungizide mischungen
NO20000519L (no) 2-acylaminopropanaminer som takykininreseptorantagonister
BR9908443A (pt) Linhagens de células de medula espinhal humana e métodos para uso das mesmas
ATE412435T1 (de) Verwendung eines färbemittels zur anfärbung von der augenlinsenkapsel oder von an der netzhaut des auges entstandenen membranen
DK0821593T3 (da) Konjugat af et aktivt middel, et protein og eventuelt et for kroppen ikke som fremmed anset nativt protein
Petitti et al. Physiologic measures in men with and without vasectomies
ATE168005T1 (de) Verwendung von procystein als depigmentierendes mittel
FI844645A0 (fi) 1,7-difenyl-3-metylaza-7-cyan-8 -metyl-nonan foer anvaendning vid bekaempning av sjukdomar.
増山元三郎 et al. Quasi-constancy of human biochemical individual variability
EP1500707A4 (en) METHOD FOR MEASURING NEPRILYSIN ACTIVITY